Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19

Phase 3 Unknown 380 enrolled Azidus Brasil Farmoquimica S.A. · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a pivotal phase III study to evaluate the efficacy of nitazoxanide 600 mg BID compared to placebo to treat hospitalized patients with non-critical COVID-19.

Timeline

Start: 2022-06-22
Primary completion: 2023-03
Completion: 2023-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nitazoxanide	Other / unclassified	600 mg	—

Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19

Summary

Timeline

Drugs

Indications